Zydus Cadila seeks DCGI nod for Hepatitis drug use in C-19 patient

The drug, originally approved for use in chronic hepatitis B and C patients

99
Zudus

Last Updated on April 7, 2021 by The Health Master

VG Somani DCGI
Dr. VG Somani, DCGI

New Delhi: Zydus Cadila has submitted its application to Dr V.G. Somani the Drugs Controller General of India (DCGI) for the repurposing of hepatitis drug PegiHep in hospitalised C-19 patients after a phase 3 clinical trial, conducted by the company, showed a single dose was significantly better in treating the acute respiratory disease.

In a phase 3 trial of 250 patients across about two dozen centres in India, Zydus Cadila found that 91.2% of patients treated with the drug were RT-PCR negative by the seventh day as compared to 78.9% in patients given standard of care.

The drug, originally approved for use in chronic hepatitis B and C patients also reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate C-19 patients in the hospital.


Also read:

Latest Notifications: New Drugs and Clinical Trials

Intoxicants: नशे के खिलाफ अभियान में मेडिकल स्टोर सील: Haryana

Johnson & Johnson testing vaccine on teens

Bharat Biotech’s Covaxin: Clinical trials for third dose allowed

No set standards available for Pharma Pollution

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner